Birchtech Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Birchtech Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.63M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $17.41M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $17.63M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $21.62M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $13.01M | May 15, 2023 |
| FY2021 | Dec 31, 2020 | $8.16M | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $11.42M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $12.30M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $27.50M | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | $32.35M | Apr 17, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $5.03M | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $2.45M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $668.5K | Mar 20, 2015 |
| FY2011 | Dec 31, 2011 | $458.1K | Dec 21, 2012 |
| FY2011 | Dec 31, 2010 | $7.0K | Dec 21, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.40M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.10M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.02M | Apr 16, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.03M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.80M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.67M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.58M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($3.63M) | May 15, 2023 |
| FY2021 | Dec 31, 2020 | ($5.83M) | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | ($6.10M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | ($4.82M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($2.90M) | Apr 11, 2019 |
| FY2017 | Dec 31, 2016 | ($15.62M) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.03M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($7.16M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($8.97M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $904.0K | Apr 16, 2024 |
| FY2018 | Dec 31, 2018 | $2.80M | Apr 11, 2019 |
| FY2017 | Dec 31, 2017 | $11.1K | Apr 17, 2018 |
| FY2016 | Dec 31, 2016 | $2.06M | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | ($3.69M) | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | ($6.48M) | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | ($4.22M) | Mar 20, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2011 | Dec 31, 2011 | $764.0K | Dec 21, 2012 |
| FY2011 | Dec 31, 2010 | $125.8K | Dec 21, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.58M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $14.22M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $14.21M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.12M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $5.93M | May 15, 2023 |
| FY2021 | Dec 31, 2020 | $5.94M | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $6.43M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $5.89M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $8.47M | Apr 11, 2019 |
| FY2016 | Dec 31, 2016 | $7.26M | Mar 28, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($700.1K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.11M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $19.23M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $71.0K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($206.0K) | May 15, 2023 |
| FY2021 | Dec 31, 2020 | ($1.24M) | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | ($1.58M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | ($1.07M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($471.7K) | Apr 11, 2019 |
| FY2016 | Dec 31, 2016 | $3.23M | Mar 28, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.3K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $809.4K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.7K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $11.0K | May 15, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 5, 2022 |
| FY2011 | Dec 31, 2011 | $1.40M | Dec 21, 2012 |
| FY2011 | Dec 31, 2010 | $1.8K | Dec 21, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.24M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.26M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $28.31M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $9.34M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $8.13M | May 15, 2023 |
| FY2021 | Dec 31, 2020 | $7.38M | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $9.27M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $8.04M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $12.06M | Apr 11, 2019 |
| FY2016 | Dec 31, 2016 | $15.88M | Mar 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.95M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.07M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $28.25M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $16.76M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $18.37M | May 15, 2023 |
| FY2021 | Dec 31, 2020 | $20.58M | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $18.15M | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | $16.66M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $16.48M | Apr 11, 2019 |
| FY2016 | Dec 31, 2016 | $20.85M | Mar 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.71M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.19M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $60.4K | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($7.42M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($10.24M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | ($13.20M) | May 15, 2023 |
| FY2021 | Dec 31, 2019 | ($8.87M) | Apr 5, 2022 |
| FY2020 | Dec 31, 2018 | ($8.62M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2017 | ($4.42M) | May 14, 2020 |
| FY2018 | Dec 31, 2016 | ($3.66M) | Apr 11, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.78M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($72.75M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($61.95M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($68.70M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($67.12M) | May 15, 2023 |
| FY2021 | Dec 31, 2020 | $63.48M | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | ($57.66M) | Apr 5, 2021 |
| FY2019 | Dec 31, 2018 | ($51.48M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($46.67M) | Apr 11, 2019 |
| FY2016 | Dec 31, 2016 | ($54.88M) | Mar 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $20.94M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $1.50M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.39M | May 15, 2023 |
| FY2021 | Dec 31, 2020 | $591.0K | Apr 5, 2022 |
| FY2021 | Dec 31, 2019 | $1.50M | Apr 5, 2022 |
| FY2020 | Dec 31, 2018 | $584.9K | Apr 5, 2021 |
| FY2019 | Dec 31, 2017 | $2.42M | May 14, 2020 |
| FY2018 | Dec 31, 2016 | $7.75M | Apr 11, 2019 |
| FY2016 | Dec 31, 2015 | $1.08M | Mar 28, 2017 |
| FY2016 | Dec 31, 2014 | $7.21M | Mar 28, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.46M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 19.24M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 94.36M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 93.09M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 89.12M | May 15, 2023 |
| FY2021 | Dec 31, 2020 | 78.10M | Apr 5, 2022 |
| FY2016 | Dec 31, 2016 | 73.51M | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | 47.19M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | 40.23M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | 35.30M | Mar 20, 2015 |